A serum factor that suppresses the cytotoxic function of cytokine-stimulated human eosinophils.
Open Access
- 1 March 1990
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 171 (3) , 681-693
- https://doi.org/10.1084/jem.171.3.681
Abstract
A human subject (NR) was identified whose eosinophils and neutrophils failed to respond to TNF in vitro in 29 of 33 experiments, using several biological assays. There was a response rate to TNF of 100% among 37 control subjects whose leukocytes were tested in parallel. NR serum contained an activity that inhibited the cytotoxic function of TNF- and GM-CSF-stimulated normal human eosinophils. A similar activity was detected in 4 of 122 control sera and in sera of two subjects with hypereosinophilia. This activity (ECI) had an apparent molecular weight of 80,000-100,000 and was sensitive to heating at 80 degrees C or to trypsin treatment. HPLC sizing chromatography increased the titer of ECI by a factor of 50 to 2,000 in experiments using NR serum or other sera with detectable inhibitory activity. In seven experiments using sera with no inhibitory activity, HPLC generated ECI of the same apparent molecular weight. The effect of HPLC on ECI activity required the separation of serum components and did not result from exposure to HPLC system components or other sample processing methods. This suggests that ECI in serum can be stabilized in an inactive or partially active form and that HPLC removes the stabilizing component. ECI suppressed TNF-stimulated eosinophil cytotoxic function when added to cultures up to 4 h after exposure of eosinophils to cytokine. However, ECI did not protect L929 cells from the toxic effects of TNF. Thus, ECI did not act by preventing the initial interaction of TNF with eosinophils or by interfering with the binding of TNF to its receptor on L929 cells. The results suggest that ECI is a component of a feedback mechanism that suppresses functions of cytokine-activated eosinophils in inflammation.This publication has 25 references indexed in Scilit:
- A human inhibitor of tumor necrosis factor alpha.The Journal of Experimental Medicine, 1988
- Three distinct classes of regulatory cytokines control endothelial cell MHC antigen expression. Interactions with immune gamma interferon differentiate the effects of tumor necrosis factor and lymphotoxin from those of leukocyte alpha and fibroblast beta interferons.The Journal of Experimental Medicine, 1988
- Modification of human serum low density lipoprotein by oxidation — Characterization and pathophysiological implicationsChemistry and Physics of Lipids, 1987
- Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis FactorHybridoma, 1987
- Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1.Proceedings of the National Academy of Sciences, 1986
- Rapid colorimetric assay for cell growth and survivalJournal of Immunological Methods, 1986
- Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.The Journal of Experimental Medicine, 1985
- Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in VitroScience, 1985
- Molecular Cloning of the Complementary DNA for Human Tumor Necrosis FactorScience, 1985
- H2O2 release from human granulocytes during phagocytosis. I. Documentation, quantitation, and some regulating factors.Journal of Clinical Investigation, 1975